NDMC101

Research use only, not for human use.

NDMC101 is an inhibitor of dipeptidyl peptidase-IV activity in human T cells and exhibits immunomodulatory effects. It also acts as a novel inhibitor of NFATc1 and NF-κB activity.NDMC101 markedly inhibited RANKL-induced formation of TRAP+ multinucleated cells in RAW264.7 and bone marrow macrophage cells (BMMs).

NDMC101 is an inhibitor of dipeptidyl peptidase-IV activity in human T cells and exhibits immunomodulatory effects. It also acts as a novel inhibitor of NFATc1 and NF-κB activity.NDMC101 markedly inhibited RANKL-induced formation of TRAP+ multinucleated cells in RAW264.7 and bone marrow macrophage cells (BMMs). Moreover, pit formation assay showed that NDMC101 significantly reduced the bone-resorbing activity of mature osteoclasts[1].In CIA mice, oral administration of NDMC101 reduced arthritic index and mitigated bone erosion. Serum TNF-α and IL-1β concentrations in these mice were decreased significantly at the higher dose of 62.5 mg/kg.

NDMC101 (10-15 μM) inhibits RANKL-induced osteoclast differentiation of bone marrow-derived macrophages (BMDMs) and RAW 264.7 cells. NDMC101 (15 μM) decreases RANKL-induced expression of the osteoclastogenic genes?Nfatc1,?Acp5,?Ctsk,?Oscar,?Itgb3, and?Dcstamp?in BMDMs.

——

——

Others

Other Targets

osteoclastogenesis

——

——

1308631-40-4

265.66

C13H9ClFNO2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (376.41 mM)

Oc1ccccc1C(=O)Nc1ccc(Cl)cc1F

——

(-20℃)

With Ice Pack

≥ 2 years